Among the millions living with chronic kidney disease, a quiet signal embedded in routine blood work may be telling us something profound about who is most at risk of dying — and why. Researchers analyzing two decades of national health data found that a simple ratio of two already-measured values, red blood cell distribution width and serum albumin, independently predicted death from all causes, heart disease, and cancer with striking consistency. The finding invites us to consider how much wisdom already lies dormant in the ordinary, and how the tools of prognosis need not always be exotic o
Routine Blood Test Ratio Predicts Mortality Risk in CKD Patients
Among 3,965 adults with CKD tracked over 88.9 months, 1,163 died including 417 from cardiovascular disease and 231 from cancer.
A simple ratio from routine blood work predicts who will die
Mark
So this is saying a simple blood test ratio can predict who's going to die? That seems almost too convenient.
Mimi
Not predict with certainty—predict risk. The ratio itself doesn't cause death. It's a marker that correlates with higher mortality, which is different. The researchers were careful about that distinction.
Luke
Right, and it's worth noting this is observational data. They're looking backward at what happened to people, not running an experiment. We don't know if changing the ratio would change outcomes.
Mark
What makes this ratio special? Why does it work better than just looking at red blood cells or albumin separately?
Mimi
That's the interesting part. Red blood cell distribution width captures inflammation and anemia. Albumin shows nutritional status. Together, they seem to tell a more complete story about who's at risk. But the effect isn't uniform—it breaks down in patients with severe protein loss.
Luke
That's a crucial caveat. In patients with macroalbuminuria, the association was much weaker. The authors themselves said to interpret it cautiously in that group. So this isn't a universal predictor.
Mark
How many people are we talking about here?
Mimi
Nearly 4,000 adults with chronic kidney disease followed for an average of about nine years. Over 1,100 of them died during that time.
Luke
And that's real data from a nationally representative survey, which is solid. But it's still one snapshot in time for each person. We don't know what happened to their RAR values over those nine years, or whether changes in the ratio would predict changes in risk.
Mark
So what's the practical next step?
Mimi
The researchers are proposing it as a low-cost screening tool. Both tests are already routine. If confirmed in prospective studies, it could help doctors identify high-risk patients earlier.
Luke
But that's the key word—if confirmed. Right now this is an association. Before any doctor changes how they manage patients based on RAR, we need prospective trials showing that identifying high-risk people actually leads to better outcomes if you intervene.
O Pulso
- Among nearly 4,000 adults with chronic kidney disease followed for almost nine years, more than one in four died — a sobering reminder of how lethal this condition remains.
- Each standard deviation rise in the RAR ratio correlated with an 81% increase in all-cause mortality risk, with cardiovascular and cancer deaths rising at comparable rates, creating urgent pressure to find better early-warning tools.
- The ratio's predictive power fractured at a specific threshold — RAR 4.258 — above which the signal weakened, and in patients with the most severe protein loss, the marker lost much of its reliability, complicating any simple clinical rollout.
- Researchers are now calling for prospective trials to validate RAR as a low-cost stratification tool, hoping to translate a dormant data point in standard lab panels into actionable clinical guidance.
Among the millions living with chronic kidney disease, a quiet signal embedded in routine blood work may be telling us something profound about who is most at risk of dying — and why. Researchers analyzing two decades of national health data found that a simple ratio of two already-measured values, red blood cell distribution width and serum albumin, independently predicted death from all causes, heart disease, and cancer with striking consistency. The finding invites us to consider how much wisdom already lies dormant in the ordinary, and how the tools of prognosis need not always be exotic or expensive to be meaningful.
A ratio hiding in plain sight within routine blood work may hold meaningful clues about mortality risk for people with chronic kidney disease. By analyzing data from nearly 4,000 adults tracked across two decades of national health surveys, researchers found that the ratio of red blood cell distribution width to serum albumin — called RAR — was independently associated with death from any cause, from cardiovascular disease, and from cancer.
Over an average follow-up of nearly nine years, 1,163 participants died. The mortality risks scaled sharply with RAR: each standard deviation increase raised all-cause mortality risk by 81%, cardiovascular mortality by 89%, and cancer mortality by 76%. Those in the highest quartile of RAR faced nearly three times the risk of dying compared to those in the lowest — associations that held after extensive statistical adjustment.
What makes the finding practically compelling is that both components are already standard. Red blood cell distribution width reflects variation in red cell size, a marker tied to anemia and inflammation. Albumin reflects nutritional status and liver function. Together, they appear to capture a dimension of mortality risk that neither conveys alone.
The relationship was not uniform. An inflection point at RAR 4.258 marked where the predictive signal began to fade, and in patients with macroalbuminuria — the most severe form of urinary protein loss — the association weakened considerably, likely because severely depressed albumin levels obscure the inflammatory signal. Older adults and men showed stronger associations in specific mortality categories.
The study's authors are careful to frame RAR as a prognostic marker, not a modifiable risk factor — changing the ratio would not itself improve survival. But if confirmed in prospective trials, RAR could offer clinicians a simple, inexpensive way to identify which patients with chronic kidney disease face the greatest danger and may benefit most from closer attention.
A simple ratio drawn from routine blood work—the kind of test millions of Americans get every year without thinking much about it—appears to predict who among people with chronic kidney disease will die in the coming years, and from what. Researchers analyzing two decades of national health data found that a higher ratio of red blood cell distribution width to serum albumin, known as RAR, was independently tied to increased risk of death from any cause, from heart disease, and from cancer.
The study examined 3,965 adults with chronic kidney disease tracked through the National Health and Nutrition Examination Survey between 1999 and 2018, with mortality follow-up extending through the end of 2019. Over an average of nearly nine years, 1,163 of these participants died. Among them, 417 deaths were attributed to cardiovascular disease and 231 to cancer. The researchers grouped participants by their RAR values, ranging from below 2.93 in the lowest quartile to 3.45 or higher in the highest, and then examined how these ratios correlated with death.
The numbers were striking. For every standard deviation increase in RAR, the risk of dying from any cause climbed by 81 percent. Cardiovascular mortality risk rose 89 percent, and cancer mortality risk increased 76 percent. When comparing the highest quartile directly to the lowest, the disparities widened further: people in the top group faced nearly three times the risk of all-cause death and nearly three times the risk of cardiovascular death compared to those in the bottom group. These associations held even after researchers adjusted for a wide range of other health factors and used statistical techniques to account for differences between groups.
Both components of the ratio come from blood tests that are already standard practice. Red blood cell distribution width measures the variation in size among red blood cells and has previously been linked to anemia and inflammation. Albumin, a protein made by the liver, signals nutritional status—low levels suggest the body is not getting or retaining adequate nutrition. The combination appears to capture something important about mortality risk that neither measure alone conveys as powerfully. A prior study in Japan had shown that higher RAR predicted progression to end-stage kidney disease, but whether it predicted death in people with chronic kidney disease remained unknown until now.
The relationship between RAR and mortality was not uniformly linear across all patients. Researchers identified an inflection point at an RAR value of 4.258. Below that threshold, the mortality risks were substantial and statistically significant. Above it, the associations weakened and were no longer statistically meaningful. The pattern differed by type of mortality: for all-cause and cardiovascular deaths, the relationship was nonlinear; for cancer deaths, it remained linear across the range studied.
Subgroup analysis revealed important variations. The connection between RAR and all-cause mortality differed depending on whether patients had protein in their urine. Among those with macroalbuminuria—the most severe form of protein loss—the association was weaker than in patients with normal urine protein or moderate protein loss. The researchers suggested that when albumin levels are markedly low due to severe kidney disease, the inflammatory signal carried by red blood cell distribution width may become obscured. They cautioned that RAR should be interpreted carefully in patients with macroalbuminuria. The associations were stronger in adults 65 and older for all-cause and cancer mortality, and stronger in men for cardiovascular and cancer mortality. Kidney function level itself did not significantly modify the relationship.
The study has limitations. RAR was measured only once per person, so the researchers could not track how changes over time might affect outcomes. Unmeasured factors—such as whether patients were taking iron supplements or certain medications—could have influenced results. Because the study was observational rather than experimental, it cannot prove that RAR causes higher mortality, only that the two are associated. The authors were explicit about this distinction, writing that RAR should be understood as a prognostic biomarker for predicting outcomes rather than as a modifiable risk factor that, if changed, would improve survival.
Yet the practical appeal is clear. Both red blood cell distribution width and albumin are measured in routine, inexpensive blood work that most people with chronic kidney disease already undergo regularly. If RAR proves reliable, it could become a straightforward tool for identifying which patients face the highest mortality risk and might benefit from more intensive monitoring or intervention. The researchers called for prospective cohort studies and randomized controlled trials to confirm these findings before RAR is adopted into clinical practice.
Citações Notáveis
RAR should be interpreted as a prognostic biomarker for mortality outcomes in CKD rather than a modifiable risk factor— Study authors
For patients with macroalbuminuria, the prognostic value of RAR should be interpreted cautiously— Study authors
Quer a matéria completa?
Leia o original em AJMC ↗